| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/ONC.2008.241 |
| P8608 | Fatcat ID | release_czzm2hchgra5llxx2xhy4ik5ey |
| P698 | PubMed publication ID | 18794879 |
| P5875 | ResearchGate publication ID | 23258301 |
| P50 | author | Wen Hong Shen | Q60309699 |
| P2093 | author name string | Y Yin | |
| P2860 | cites work | The lipid phosphatase activity of PTEN is critical for its tumor supressor function | Q22007981 |
| The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region | Q22010498 | ||
| NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN | Q24292919 | ||
| Ubiquitination regulates PTEN nuclear import and tumor suppression | Q24292946 | ||
| A limited screen for protein interactions reveals new roles for protein phosphatase 1 in cell cycle control and apoptosis | Q24295142 | ||
| Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function | Q24311568 | ||
| Growth suppression by p16ink4 requires functional retinoblastoma protein | Q24317567 | ||
| The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate | Q24317714 | ||
| Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN | Q24322051 | ||
| P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 | ||
| PTEN function: how normal cells control it and tumour cells lose it | Q24528114 | ||
| Protean PTEN: form and function | Q24613810 | ||
| Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma | Q57591227 | ||
| The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer | Q57977987 | ||
| High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice | Q58378937 | ||
| Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production | Q64965662 | ||
| Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 | Q67521108 | ||
| Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis | Q74116705 | ||
| PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway | Q74404969 | ||
| PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells | Q81877328 | ||
| Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. | Q55476215 | ||
| PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner | Q57591077 | ||
| Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN | Q57591094 | ||
| GI polyposis and glycogenic acanthosis of the esophagus associated with PTEN mutation positive Cowden syndrome in the absence of cutaneous manifestations | Q57591191 | ||
| Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas | Q57591220 | ||
| Protein modules as organizers of membrane structure | Q33712466 | ||
| The multiple roles of PTEN in tumor suppression | Q33849727 | ||
| Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. | Q34477787 | ||
| P53 is a tumor suppressor gene | Q34546732 | ||
| p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control | Q34718105 | ||
| The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network | Q34825957 | ||
| TP53 and breast cancer | Q35078761 | ||
| Membrane-binding and activation mechanism of PTEN. | Q35145882 | ||
| PTEN: from pathology to biology | Q35208577 | ||
| Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells | Q35745875 | ||
| Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors | Q35810225 | ||
| Human cancer, PTEN and the PI-3 kinase pathway | Q35812408 | ||
| The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics | Q35884334 | ||
| TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer | Q35906287 | ||
| Identification of a tumour suppressor network opposing nuclear Akt function | Q35991130 | ||
| PTEN: a novel anti-oncogenic function independent of phosphatase activity | Q36064643 | ||
| Life, death, and ubiquitin: taming the mule. | Q36179907 | ||
| Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways | Q36256326 | ||
| Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis | Q36384467 | ||
| PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). | Q36497447 | ||
| PTEN enters the nuclear age. | Q36705731 | ||
| PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex | Q36710785 | ||
| PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-kappaB and AP-1 in vascular smooth muscle cells | Q38518162 | ||
| Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases | Q38525479 | ||
| PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway | Q40181453 | ||
| Nuclear localization of PTEN is regulated by Ca(2+) through a tyrosil phosphorylation-independent conformational modification in major vault protein | Q40192972 | ||
| PTEN enters the nucleus by diffusion | Q40387100 | ||
| Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein | Q40421181 | ||
| Genomic Integrity and the Genetics of Cancer | Q40431181 | ||
| Lack of PTEN sequesters CHK1 and initiates genetic instability. | Q40458578 | ||
| Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. | Q40587498 | ||
| PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells | Q40639993 | ||
| Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray | Q40857263 | ||
| PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. | Q40911230 | ||
| Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation | Q42076186 | ||
| Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. | Q42807109 | ||
| Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. | Q43918911 | ||
| Identification of germline mutation of PTEN gene and analysis of apoptosis resistance of the lymphocytes in a patient with Cowden disease | Q44204219 | ||
| The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity | Q44546646 | ||
| Regulation of p53 by Mdm2: fate is in the numbers | Q44734147 | ||
| PTEN regulates Mdm2 expression through the P1 promoter | Q44848220 | ||
| Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease | Q47198022 | ||
| PTEN and inherited hamartoma-cancer syndromes | Q47852476 | ||
| Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Q24653458 | ||
| PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration | Q24677034 | ||
| Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis | Q24681977 | ||
| Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association | Q27620298 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| Surfing the p53 network | Q28032484 | ||
| PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms | Q28181035 | ||
| PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model | Q28202775 | ||
| PTEN: one gene, many syndromes | Q28203387 | ||
| PTEN: life as a tumor suppressor | Q28203431 | ||
| p21 is a universal inhibitor of cyclin kinases | Q28257305 | ||
| The biology and clinical relevance of the PTEN tumor suppressor pathway | Q28272157 | ||
| Regulation of c-Met-dependent gene expression by PTEN | Q28290742 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression | Q28505099 | ||
| Pten is essential for embryonic development and tumour suppression | Q28509238 | ||
| Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN | Q28513537 | ||
| Essential role for nuclear PTEN in maintaining chromosomal integrity | Q28513781 | ||
| Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase | Q28567492 | ||
| Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems | Q28586004 | ||
| PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway | Q28588309 | ||
| Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours | Q29547697 | ||
| A role for nuclear PTEN in neuronal differentiation. | Q29568319 | ||
| A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia | Q29615437 | ||
| Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome | Q29615538 | ||
| Cancer. p53, guardian of the genome | Q29615610 | ||
| New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway | Q29616144 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma | Q29618817 | ||
| p53 is required for radiation-induced apoptosis in mouse thymocytes | Q29620281 | ||
| Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 | Q29622924 | ||
| PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit | Q30308560 | ||
| PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity | Q30434033 | ||
| Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten | Q30524175 | ||
| PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways | Q31837554 | ||
| PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells | Q33586807 | ||
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5443-5453 | |
| P577 | publication date | 2008-09-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | PTEN: a new guardian of the genome | |
| P478 | volume | 27 |
| Q92405703 | A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements |
| Q98303321 | A compendium of mutational cancer driver genes |
| Q26849503 | A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy |
| Q28245811 | A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication |
| Q33873840 | A genome-wide siRNA screen identifies novel phospho-enzymes affecting Wnt/β-catenin signaling in mouse embryonic stem cells |
| Q40298545 | A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel |
| Q88175725 | A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer |
| Q38893862 | A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes. |
| Q47886038 | AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11. |
| Q35983805 | AML sensitivity to YM155 is modulated through AKT and Mcl-1. |
| Q92876654 | Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples |
| Q58113811 | Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma |
| Q38893164 | Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer |
| Q35684972 | Akt and PTEN: beta-cell mass and pancreas plasticity. |
| Q33727905 | Alkylation of the tumor suppressor PTEN activates Akt and β-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer |
| Q36942597 | Analysis of PTEN expression in large intestine polyps and its relation to the recognized histopathological and clinical risk factors for cancer development in this location |
| Q32178019 | Apoptosis-induced effects of extract from Artemisia annua Linné by modulating PTEN/p53/PDK1/Akt/ signal pathways through PTEN/p53-independent manner in HCT116 colon cancer cells |
| Q33716992 | Association between PTEN Gene IVS4 polymorphism and risk of cancer: a meta-analysis |
| Q83453420 | Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma |
| Q38953487 | Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer |
| Q35591562 | Autophagy as a therapeutic target in cancer. |
| Q35146596 | Autophagy: cancer's friend or foe? |
| Q35019216 | CREB is a novel nuclear target of PTEN phosphatase |
| Q58129865 | Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis |
| Q93198746 | Cancer of Unknown Primary Site: Real Entity or Misdiagnosed Disease? |
| Q35106673 | Carney complex and lentiginosis |
| Q33793077 | Cdh1, a substrate-recruiting component of anaphase-promoting complex/cyclosome (APC/C) ubiquitin E3 ligase, specifically interacts with phosphatase and tensin homolog (PTEN) and promotes its removal from chromatin |
| Q39753163 | Cell cycle arrest induced by engagement of B7-H4 on Epstein-Barr virus-positive B-cell lymphoma cell lines |
| Q36655944 | Cell survival and apoptosis signaling as therapeutic target for cancer: marine bioactive compounds |
| Q35678658 | Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response |
| Q28073246 | Chemoresistance and targeted therapies in ovarian and endometrial cancers |
| Q55068347 | Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. |
| Q35204410 | Clinical and molecular heterogeneity in brazilian patients with sotos syndrome |
| Q46710025 | Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients |
| Q38961297 | Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response? |
| Q64099686 | Complex Systems Biology Approach in Connecting PI3K-Akt and NF-κB Pathways in Prostate Cancer |
| Q42519337 | Comprehensive analysis of PTEN status in breast carcinomas |
| Q28397537 | Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities |
| Q58704022 | Concomitant p53 and PTEN immunoexpression to predict the risk of malignancy in endometrial polyps |
| Q38120310 | Control of oncogenesis by eIF2α phosphorylation: implications in PTEN and PI3K-Akt signaling and tumor treatment |
| Q53280318 | Cross-talk between endothelial cells and tumor via delta-like ligand 4/Notch/PTEN signaling inhibits lung cancer growth. |
| Q92702430 | Crosstalk between PTEN/PI3K/Akt Signalling and DNA Damage in the Oocyte: Implications for Primordial Follicle Activation, Oocyte Quality and Ageing |
| Q52679071 | Current Insights into Oral Cancer Epigenetics. |
| Q37600799 | DNA repair in cancer: emerging targets for personalized therapy. |
| Q90216237 | Deficiency of PTEN leads to aberrant chromosome segregation through downregulation of MAD2 |
| Q57211763 | Detection of a novel, primate-specific 'kill switch' tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53 |
| Q42383055 | Does PTEN gene mutation play any role in Li-Fraumeni syndrome |
| Q37815607 | Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma |
| Q36392466 | Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency |
| Q34638183 | Genetic alterations in colorectal cancer. |
| Q36563659 | Genetics of melanoma |
| Q92002414 | Grb2 binds to PTEN and regulates its nuclear translocation to maintain the genomic stability in DNA damage response |
| Q98289772 | HBV infection exacerbates PTEN defects in hepatocellular carcinoma through upregulation of miR-181a/382/362/19a |
| Q33925330 | HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines |
| Q38941133 | Hepatitis C virus NS5A drives a PTEN-PI3K/Akt feedback loop to support cell survival |
| Q39036145 | Hereditary syndromes predisposing to endocrine tumors and their skin manifestations |
| Q33487434 | High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line |
| Q24313224 | Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells |
| Q49922823 | How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? |
| Q38308779 | Immunohistochemical assessment of PTEN in vulvar cancer: best practices for tissue staining, evaluation, and clinical association. |
| Q37589232 | In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player. |
| Q35379204 | Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress |
| Q39101629 | Insulin activates the insulin receptor to downregulate the PTEN tumour suppressor |
| Q38878851 | JAK-STAT signaling in cancer: From cytokines to non-coding genome. |
| Q27025213 | Killing me softly--future challenges in apoptosis research |
| Q58732829 | Long non-coding RNAs in esophageal cancer: molecular mechanisms, functions, and potential applications |
| Q33633647 | Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis |
| Q34876968 | MCT-1 expression and PTEN deficiency synergistically promote neoplastic multinucleation through the Src/p190B signaling activation |
| Q39093841 | Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma |
| Q41126784 | MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance |
| Q38837100 | MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN. |
| Q47152852 | Microsatellite Alterations and Protein Expression of 5 Major Tumor Suppressor Genes in Gastric Adenocarcinomas |
| Q37225495 | Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1. |
| Q33843600 | Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide s |
| Q38402223 | Molecular alterations in endometrial archived liquid-based cytology. |
| Q24617331 | Molecular origins of cancer: Molecular basis of colorectal cancer |
| Q50932512 | Multiple functions of insulin-degrading enzyme: a metabolic crosslight? |
| Q34194294 | Muscle-specific inositide phosphatase (MIP/MTMR14) is reduced with age and its loss accelerates skeletal muscle aging process by altering calcium homeostasis |
| Q26767396 | Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways |
| Q37304241 | No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer |
| Q38936710 | Novel Approaches to Apoptosis-Inducing Therapies |
| Q33551348 | Novel mechanism of tumor suppression by polarity gene discs large 1 (DLG1) revealed in a murine model of pediatric B-ALL. |
| Q55212155 | Nuclear PTEN safeguards pre-mRNA splicing to link Golgi apparatus for its tumor suppressive role. |
| Q39159757 | Nuclear phosphoinositide regulation of chromatin. |
| Q39238259 | Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia |
| Q28079556 | Obesity and colorectal cancer: molecular features of adipose tissue |
| Q47232136 | Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression |
| Q84145725 | Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells |
| Q46976450 | PI3K/AKT pathway activation in bladder carcinogenesis |
| Q38007118 | PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas |
| Q33968025 | PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha |
| Q87980403 | PTEN Mutation Identified in Patient Diagnosed with Simultaneous Multiple Cancers |
| Q34514602 | PTEN and p53 cross-regulation induced by soy isoflavone genistein promotes mammary epithelial cell cycle arrest and lobuloalveolar differentiation |
| Q52661710 | PTEN at the interface of immune tolerance and tumor suppression. |
| Q37164566 | PTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle |
| Q38915989 | PTEN deletion potentiates invasion of colorectal cancer spheroidal cells through 3D Matrigel |
| Q39201094 | PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells |
| Q40671461 | PTEN gene polymorphisms and susceptibility to oral squamous cell carcinoma in a Chinese Han population |
| Q34124806 | PTEN inhibition to facilitate intrinsic regenerative outgrowth of adult peripheral axons. |
| Q34364654 | PTEN interacts with histone H1 and controls chromatin condensation |
| Q33857310 | PTEN is a negative regulator of mitotic checkpoint complex during the cell cycle |
| Q33958963 | PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. |
| Q53804306 | PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy. |
| Q37166155 | PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis |
| Q39615345 | PTEN regulates PLK1 and controls chromosomal stability during cell division |
| Q39377876 | PTEN: A potential prognostic marker in virus-induced hepatocellular carcinoma. |
| Q38406254 | PTEN: a yin-yang master regulator protein in health and disease |
| Q42921293 | PTENtumor suppressor plays less prognostic role thanP53tumor suppressor in diffuse large B-cell lymphoma |
| Q38269777 | Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. |
| Q40436436 | Phosphatase and Tensin Homolog Is a Growth Repressor of Both Rhizoid and Gametophore Development in the Moss Physcomitrella patens. |
| Q38696613 | Phosphatase and tensin homolog (PTEN) expression on oncologic outcome in renal cell carcinoma: A systematic review and meta-analysis |
| Q34016649 | Phospholipase C isozymes are deregulated in colorectal cancer--insights gained from gene set enrichment analysis of the transcriptome |
| Q33917649 | Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers |
| Q33619449 | Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle |
| Q37826009 | Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic |
| Q28473591 | Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons |
| Q41198110 | Profiling of the metabolic transcriptome via single molecule molecular inversion probes. |
| Q36013408 | Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma |
| Q58123755 | Protective Effects of Silymarin and Silibinin against DNA Damage in Human Blood Cells |
| Q35165208 | Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling |
| Q35775566 | Proteins interaction network and modeling of IGVH mutational status in chronic lymphocytic leukemia |
| Q35823331 | Pten regulates collective cell migration during specification of the anterior-posterior axis of the mouse embryo |
| Q34420665 | RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. |
| Q64055629 | Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms |
| Q33721146 | Regional differences in gallbladder cancer pathogenesis: insights from a comparison of cell cycle-regulatory, PI3K, and pro-angiogenic protein expression |
| Q28512686 | Regulation of PTEN Stability and Activity by Plk3 |
| Q38185970 | Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery |
| Q33825098 | Ribosomal DNA copy number loss and sequence variation in cancer |
| Q38174514 | Ribosomal proteins as novel players in tumorigenesis |
| Q37893976 | Risk factors for autism: translating genomic discoveries into diagnostics |
| Q35161917 | Role and regulation of autophagy in cancer |
| Q92661639 | Role of Cytosolic 2-Cys Prx1 and Prx2 in Redox Signaling |
| Q47243959 | SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis |
| Q27024675 | Sapacitabine for cancer |
| Q38829862 | Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes |
| Q91942269 | Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation |
| Q42474267 | Shifting the balance of mitochondrial apoptosis: therapeutic perspectives |
| Q39766760 | Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation |
| Q38845654 | Sox2: regulation of expression and contribution to brain tumors |
| Q37801265 | Synthetic lethal approaches to breast cancer therapy |
| Q37223362 | Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase |
| Q28072904 | Synthetic lethality in lung cancer and translation to clinical therapies |
| Q64246967 | Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells |
| Q37366157 | Targeting SRC and tubulin in mucinous ovarian carcinoma |
| Q51057342 | The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer. |
| Q91826180 | The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response |
| Q36137883 | The Optimization of Soluble PTEN Expression in Escherichia coli |
| Q41460864 | The PI3K-PTEN tug-of-war, oxidative stress and retinal degeneration |
| Q54274892 | The PI3K/AKT/mTOR interactive pathway. |
| Q37506648 | The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma |
| Q51767323 | The Yokohama system for reporting directly sampled endometrial cytology: The quest to develop a standardized terminology. |
| Q53235759 | The association of phosphatase and tensin homolog deleted on chromosome 10 polymorphisms and lifestyle habits with colorectal cancer risk in a Chinese population. |
| Q38124258 | The emerging role of RNA polymerase I transcription machinery in human malignancy: a clinical perspective. |
| Q34160931 | The emerging role of pseudogene expressed non-coding RNAs in cellular functions |
| Q36268915 | The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy |
| Q35076580 | The expression of microRNA-451 in human endometriotic lesions is inversely related to that of macrophage migration inhibitory factor (MIF) and regulates MIF expression and modulation of epithelial cell survival |
| Q54112403 | The impact of phosphatases on proliferative and survival signaling in cancer. |
| Q47721081 | The long noncoding RNA CASC2 inhibits tumorigenesis through modulating the expression of PTEN by targeting miR-18a-5p in esophageal carcinoma |
| Q34886859 | The mTOR signaling pathway as a treatment target for intracranial neoplasms |
| Q35983641 | The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. |
| Q33906083 | The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer. |
| Q37726457 | The regulation of protein synthesis in cancer |
| Q24631438 | Therapeutic Implications of Targeting AKT Signaling in Melanoma |
| Q38946538 | Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress. |
| Q27852764 | Therapeutic targeting of cancers with loss of PTEN function |
| Q88714175 | Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics |
| Q58770422 | Tracing the path of cancer initiation: the AA protein-based model for cancer genesis |
| Q28081287 | Tumor Suppressor Inactivation in the Pathogenesis of Adult T-Cell Leukemia |
| Q39759975 | Tumor suppression by PTEN requires the activation of the PKR-eIF2alpha phosphorylation pathway |
| Q41193147 | Tumour heterogeneity poses a significant challenge to cancer biomarker research. |
| Q35545322 | Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes |
| Q53279286 | [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology]. |
| Q38973879 | miR-106b is overexpressed in medulloblastomas and interacts directly with PTEN. |
| Q39900183 | p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells. |
Search more.